Collectively, because the C’ gene is silenced or lowly expressed in the corresponding normal lineage for promoter-hijacking-like fusions, we propose that corresponding C’ genes (RUNX1T1, PBX1, GLIS2, AFDN, FLI1, and MYH11) can serve as good drug targets because the expected “on-target, off-tumor” toxicity can be minimal to the normal cells of the corresponding lineage of cancer cells (but not for other normal cells where the C’ gene has housekeeping expression). This evidence concerns the gene RUNX1T1 and cancer.